Major drug firms agree with Ban Ki-Moon to invest more in AIDS treatments & diagnostics for poor regions

Get RSS feed of these results

All components of this story

Article
10 October 2008

Drug firms agree to invest more in AIDS research-UN

Author: Louis Charbonneau, Reuters

U.N. Secretary-General Ban Ki-moon said on Thursday that major pharmaceutical firms promised to invest more on researching treatments for the AIDS virus and diagnostic procedures for poorer regions. The companies also agreed to invest more in prevention, including vaccines and pre- and post-exposure prophylaxis, Ban said in a statement issued after he met with top executives at pharmaceutical and diagnostic firms... The senior executives Ban and other U.N. officials met with were from 17 companies, including Abbott Labs, Boehringer Ingelheim, GlaxoSmithKline, Pfizer... Ban said the companies agreed to "invest further in research and development of new HIV-related medicines adapted to resource-limited settings..." -- in other words, to try to make drugs available to people in poor environments.

Read the full post here

Article
9 October 2008

Secretary-General's statement following meeting with pharmaceutical and diagnostic companies working on HIV and AIDS

Author: United Nations

I met today with senior executives of seventeen of the world's research-based and generic pharmaceutical and diagnostic companies…to review progress on...expand[ing] access to HIV prevention, treatment, care and support services in low- and middle-income countries...[C]ompanies have committed individually…to: Invest further in research and development of new HIV-related medicines adapted to resource limited settings to be used safely in children, adolescents, adults and pregnant women; Invest further in developing reliable and affordable technologies to diagnose HIV and TB (among people living with HIV) and to monitor the efficacy of treatment; Enhance efforts towards urgently needed Universal Access to infant HIV diagnosis; Invest further in research and development of new biomedical HIV prevention technologies, including vaccines, microbicides and pre and post-exposure prophylaxis…[T]he UN system agreed to:…Continue to strengthen WHO prequalification programme for urgently needed essential medicines and diagnostics; Promote information sharing between the UN, national regulatory authorities and the companies in the prequalification process…Convene…technical consultations among HIV experts and between the UN and the companies on pediatric formulations and second- and third -line regimens for adults…We agreed to continuing to hold periodic high-level meetings, under the leadership of UNAIDS, to take stock of progress and to identify new collaborative measures. [Participating companies: Abbott, Aspen, Aurobindo, Becton Dickinson, bioMerieux, Boehringer Ingelheim, Gilead Sciences, GlaxoSmithKline, Hetero, Inverness Medical Innovations, Johnson & Johnson, Matrix, Merck, Pfizer, Ranbaxy, Roche, Shanghai Kehua Bio-Engineering]

Read the full post here